The investment fund Synven is close to acquiring BioAgilytix, the US company that conducts experiments in the pharmaceutical and biotech sector. Cobepa, Belgium’s major partner in BioAgilytix, could receive a solid penny for the deal.
BioAgilytix is a CRO (contract research organization), a company that outsources part of their research and development to pharmaceutical and biotechnology companies. It works for pharmaceutical companies such as Gilead, Novartis and Biogen.
Kobe bought the company At the end of 2018 Sold a few shares a few months later. The Belgian investment firm still has a majority stake of 52 percent. Management and British investor Caledonia, Kobeba’s partner are also in the group.
But Bloomberg said the cards would be replaced soon. The news agency reports that the investment fund Sinven is close to acquiring BioAgilytix. The fund, owned by German medical laboratory operator Sinlab, is valued at $ 2.5 billion (2. 2.2 billion) in North Carolina.
It is unknown at this time what he will do after leaving the post.
It is unknown at this time what he will do with the money – but it is unknown at this time what he will do after leaving the post. According to Bloomberg, the Belgian investment firm will reinvest in the US company next to Sinwen.
BioAgilytix is not Kobe’s only holding in the United States. The Belgian investor owns more than half of the AB Infeve de Spoleberch family.Has been active since 2015. Kobe is also on the team with General II, a specialist in orthopedic surgery (a company that plays a key role in the back office of investment funds). Precise orthopedics On Heartland Home Services, A mid-level American player in craft services.
“Passionate analyst. Thinker. Devoted twitter evangelist. Wannabe music specialist.”
Investors look to inflation data and US debt ceiling | economy
Debt Struggles in America: It’s Affecting Us Too
Just a little more time for the loan agreement: in the US only June 5 will settle | Abroad